Aprea Therapeutics Inc (APRE)
4.705
+0.10
(+2.13%)
USD |
NASDAQ |
May 31, 16:00
4.55
-0.16
(-3.29%)
After-Hours: 20:00
Aprea Therapeutics Research and Development Expense (Quarterly): 1.600M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.600M |
| December 31, 2023 | 2.046M |
| September 30, 2023 | 2.123M |
| June 30, 2023 | 2.203M |
| March 31, 2023 | 1.256M |
| December 31, 2022 | 0.5314M |
| September 30, 2022 | 1.118M |
| June 30, 2022 | 6.812M |
| March 31, 2022 | 4.090M |
| December 31, 2021 | 4.462M |
| September 30, 2021 | 6.016M |
| June 30, 2021 | 6.654M |
| Date | Value |
|---|---|
| March 31, 2021 | 6.764M |
| December 31, 2020 | 9.328M |
| September 30, 2020 | 8.761M |
| June 30, 2020 | 10.69M |
| March 31, 2020 | 9.096M |
| December 31, 2019 | 8.042M |
| September 30, 2019 | 4.910M |
| June 30, 2019 | 4.320M |
| March 31, 2019 | 3.678M |
| December 31, 2018 | 4.395M |
| September 30, 2018 | 2.307M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.5314M
Minimum
Dec 2022
10.69M
Maximum
Jun 2020
5.041M
Average
4.686M
Median
Research and Development Expense (Quarterly) Benchmarks
| NeuBase Therapeutics Inc (DELISTED) | 0.3876M |
| Stoke Therapeutics Inc | 22.37M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |